<DOC>
	<DOCNO>NCT00603902</DOCNO>
	<brief_summary>The purpose study assess weight loss effect lorcaserin end 1 year treatment overweight obese patient .</brief_summary>
	<brief_title>BLOSSOM : Behavioral Modification Lorcaserin Second Study Obesity Management</brief_title>
	<detailed_description>Randomized , double-blind , placebo-controlled , parallel-group assessment effect lorcaserin hydrochloride 52 week administration overweight obese male female volunteer age 18 65 year inclusive .</detailed_description>
	<mesh_term>Obesity</mesh_term>
	<criteria>Overweight and/or obese men woman body mass index ( BMI ) 30 45 kg/m2 without comorbid condition ( e.g. , hypertension , dyslipidemia , CV disease , glucose intolerance , sleep apnea ) , 27 29.9 kg/m2 least one comorbid condition . Ability complete 1 year study Pregnancy Diabetes mellitus ( type I , II ) History symptomatic heart valve disease Serious unstable current past medical condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Obesity</keyword>
	<keyword>Weight loss</keyword>
	<keyword>lorcaserin</keyword>
	<keyword>APD356</keyword>
	<keyword>BLOSSOM</keyword>
	<keyword>Hypertension</keyword>
	<keyword>Dyslipidemia</keyword>
	<keyword>Sleep apnea</keyword>
	<keyword>glucose tolerance</keyword>
	<keyword>cardiovascular disease</keyword>
	<keyword>Arena</keyword>
</DOC>